ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 2521

Do Type II Symptoms Predict Complementary and Integrative Health Usage Among People Living with Systemic Lupus Erythematosus?

Jerik Leung1, Joonsuk Park2, Wendy Hartogensis3, Patti Katz4 and Sarah Patterson5

Affiliations: 1Emory University, Rollins School of Public Health, Atlanta, GA, 2University of California, San Francisco, San Francisco, CA, 3University of California, San Francisco, San Francisco, 4UCSF, San Rafael, CA, 5University of California, San Francisco, Pacifica, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: health behaviors, Patient reported outcomes, Systemic lupus erythematosus (SLE), Therapy, complementary

Session Information

Date: Tuesday, November 10, 2026

Title: (2519-2539) Patient Outcomes, Preferences, & Attitudes Poster C

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: A posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the Type 1/Type 2 model. Type 1 manifestations represent classic signs and symptoms of SLE, link to immune-mediated inflammatory pathways, and generally respond to immunosuppressive therapy; type 2 manifestations represent symptoms such as fatigue, widespread pain, cognitive dysfunction, and depressive symptoms that do not respond to the same treatments and represent an area of major unmet need. Type 2 symptoms may be most effectively addressed through non-pharmacologic interventions, yet use of complementary and integrative health (CIH) modalities among people with SLE is understudied. This study characterized the prevalence of CIH usage and its associations with patient-reported outcomes (PROs), including Type 2 symptoms.

Methods:

We used data from the California Lupus Epidemiology Study (CLUES), a prospective population-based cohort of individuals with SLE in the San Francisco Bay Area with annual data collection. PROs measured at year 5 included: PROMIS Pain Interference 4a, PROMIS Fatigue 4a, patient-reported disease activity (via SLE Disease Activity Questionnaire [SLAQ]), and depressive symptoms (via Patient Health Questionnaire [PHQ-8]). In the CLUES Year 6 interviews, we queried participant use of CIH providers (e.g., acupuncturist, homeopath, nutritionist) and CIH modalities (e.g., nutrition, mind-body exercise, supplement usage). Primary analyses comprised two multivariable logistic regression models with PROs as predictors and CIH usage, defined as either having visited a CIH provider or used a CIH modality: (1) cross-sectional and (2) time-lagged with PROs modeled at the preceding annual data collection. Analyses were adjusted for age, sex, race and ethnicity, educational attainment, disease duration, and cardiovascular disease.

Results: The sample (n=251) was 91% female, 33% white, 30% Asian, 26% Hispanic, and 9% African American; mean age 50 (± 14) years; 68% with a college degree; mean disease duration 23 (± 11) years; and 13% on glucocorticoid therapy with ≥ 7.5 mg/day prednisone equivalent. Prevalence of visiting any CIH provider was 11% (n=27) (Figure 1a), using at least one CIH modality was 47% (n=119) (Figure 1b), and any CIH use (provider and/or modality) was 49% (n=124). In the multivariable cross-sectional analysis, all 4 PROs associated with increased odds of CIH use (Table 1). In the time lagged analysis, greater pain interference, patient-reported disease activity, and depressive symptoms at T5 associated with higher odds of using CIH at T6, even after adjusting for covariates (Table 2).

Conclusion: Among a diverse SLE cohort, CIH use was common, with many participants reporting use of at least one CIH modality. Both cross-sectional and time-lagged analyses demonstrated significant associations between worse Type 2 symptoms, which are highly relevant to the experience of living with SLE, and higher odds of using CIH. Findings suggest strong interest in CIH among patients with SLE and support further investigation into the potential role of CIH interventions to addressing key dimensions of impaired quality of life among people with SLE.

Supporting image 1Figure 1. Frequency of Using Complementary and Integrative Health (CIH) Among Lupus Patients (Figure 1a: n=27; Figure 1b n=119)

Supporting image 2Table 1. Cross-sectional Multivariable Logistic Regression for Association of Type 2 SLE Manifestations with Odds of CIH Use (n = 250)

Supporting image 3Table 2. Time-lagged Multivariable Logistic Regression for Association of Type 2 SLE Manifestations at T5 with Odds of CIH Use at T6 (n = 218)


Disclosures: J. Leung: None; J. Park: None; W. Hartogensis: None; P. Katz: None; S. Patterson: None.

To cite this abstract in AMA style:

Leung J, Park J, Hartogensis W, Katz P, Patterson S. Do Type II Symptoms Predict Complementary and Integrative Health Usage Among People Living with Systemic Lupus Erythematosus? [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/do-type-ii-symptoms-predict-complementary-and-integrative-health-usage-among-people-living-with-systemic-lupus-erythematosus/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-type-ii-symptoms-predict-complementary-and-integrative-health-usage-among-people-living-with-systemic-lupus-erythematosus/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology